Sugi Predict

Sugi Predict / Compounds / SCHEMBL402758

SCHEMBL402758

SCHEMBL402758

O=C1OC2(c3ccc(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)cc3Oc3cc(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)ccc32)c2ccccc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 1/20 0.55
▸ MEN1 O00255 2/20 0.54
▸ MAPT P10636 2/20 0.54
▸ HTT P42858 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ USP2 O75604 1/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ LMNA P02545 1/20 0.54
▸ FTO Q9C0B1 2/20 0.50
▸ HPGD P15428 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ RECQL P46063 1/20 0.50
▸ BLM P54132 1/20 0.50
▸ SMAD3 P84022 1/20 0.50
▸ PRMT1 Q99873 1/20 0.50
▸ ACE2 Q9BYF1 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ TYR P14679 2/20 0.46
▸ CA12 O43570 3/20 0.46
▸ CA9 Q16790 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20777529 1.00 CYP3A4 (0.55) CYP3A4MEN1MAPTHTTKMT2A
SCHEMBL29435913 1.00 CYP3A4 (0.55) CYP3A4MEN1MAPTHTTKMT2A
SCHEMBL148323 1.00 CYP3A4 (0.55) CYP3A4MEN1MAPTHTTKMT2A
SCHEMBL2438277 1.00 CYP3A4 (0.55) CYP3A4MEN1MAPTHTTKMT2A
SCHEMBL10606489 1.00 CYP3A4 (0.55) CYP3A4MEN1MAPTHTTKMT2A
SCHEMBL1032639 1.00 CYP3A4 (0.55) CYP3A4MEN1MAPTHTTKMT2A
SCHEMBL322869 1.00 CYP3A4 (0.55) CYP3A4MEN1MAPTHTTKMT2A
SCHEMBL30816695 1.00 CYP3A4 (0.55) CYP3A4MEN1MAPTHTTKMT2A
SCHEMBL1030437 0.99 CYP3A4 (0.56) CYP3A4MEN1MAPTHTTKMT2A
SCHEMBL869219 0.95 MAPT (0.59) CYP3A4MEN1MAPTHTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2459229-B1 USE OF CONSTRAINED DIPEPTIDE AND TRIPEPTIDE MIMIC OLIGOMERS AS VECTORIZATION AGENTS CENTRE NATIONAL DE LA RECHERCHE SCIENT (C N R S ) (FR) 2018-02-28 — — EP claimed
US-9061069-B2 Use of constrained peptide mimic oligomers as vectorization agents CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-06-23 — — US claimed
US-11299590-B2 Process for preparation of bioorganic nylon polymers and their use as antibacterial material UNIVERSITE DE MONTPELLIER 2022-04-12 — — US disclosed
US-20210393855-A1 NEW HYDROGELS HAVING A SILYLATED STRUCTURE, AND METHOD FOR OBTAINING SAME UNIVERSITE DE MONTPELLIER (FR) 2021-12-23 — — US disclosed
WO-2021015218-A1 PREVENTION OR TREATMENT OF FIBROTIC DISEASE WHICH TARGETS TRANSCRIPTION-ASSOCIATED FACTOR 国立大学法人九州大学 2021-01-28 — — WO disclosed
US-20200399632-A1 SENSOR SYSTEMS ENEVOLV, INC. 2020-12-24 — — US disclosed
US-20180200408-A1 NEW HYDROGELS HAVING A SILYLATED STRUCTURE, AND METHOD FOR OBTAINING SAME UNIVERSITE DE MONTPELLIER (FR) 2018-07-19 — — US disclosed
EP-2459229-B1 USE OF CONSTRAINED DIPEPTIDE AND TRIPEPTIDE MIMIC OLIGOMERS AS VECTORIZATION AGENTS CENTRE NATIONAL DE LA RECHERCHE SCIENT (C N R S ) (FR) 2018-02-28 — — EP disclosed
EP-3269822-A1 METHODS AND COMPOSITIONS TO DETECT A BIOLOGICAL ACTIVITY 3M Innovative Properties Company (US) 2018-01-17 — — EP disclosed
EP-2643471-B1 METHODS AND COMPOSITIONS TO DETECT A BIOLOGICAL ACTIVITY 3M INNOVATIVE PROPERTIES CO (US) 2017-08-30 — — EP disclosed
EP-3178867-A1 PROCESS FOR PREPARATION OF BIOORGANIC NYLON POLYMERS AND THEIR USE AS ANTIBACTERIAL MATERIAL UNIVERSITE DE MONTPELLIER (FR) 2017-06-14 — — EP disclosed
WO-2005075440-A1 2- (PHENYLAMINO) -PYRIMIDIN-5-AMIDES AS CANNABINOID 2 RECEPTORS MODULATORS FOR THE TREATMENT OF IMMUNE OR INFLAMMATORY DISORDERS GLAXO GROUP LIMITED (GB) 2005-08-18 — — WO disclosed
WO-2005075464-A1 PYRIDINE DERIVATIVES AS CONNABINOID RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2005-08-18 — — WO disclosed
EP-1546366-A1 METHOD FOR DETECTING AND COUNTING MICRO-ORGANISMS IN A SAMPLE Metis Biotechnologies (FR) 2005-06-29 — — EP disclosed
EP-1539712-A1 PYRIMIDINE DERIVATIVES AND THEIR USE AS CB2 MODULATORS GLAXO GROUP LIMITED (GB) 2005-06-15 — — EP disclosed
EP-1534687-A1 PYRIMIDINE COMPOUNDS GLAXO GROUP LIMITED (GB) 2005-06-01 — — EP disclosed
US-20040219535-A1 Sensor system for saccharides BAXTER HEALTHCARE SA (CH) 2004-11-04 — — US disclosed
WO-2004031403-A1 METHOD FOR DETECTING AND COUNTING MICRO-ORGANISMS IN A SAMPLE METIS BIOTECHNOLOGIES (FR) 2004-04-15 — — WO disclosed
WO-2004018434-A1 PYRIMIDINE COMPOUNDS GLAXO GROUP LIMITED (GB) 2004-03-04 — — WO disclosed
WO-2004018433-A1 PYRIMIDINE DERIVATIVES AND THEIR USE AS CB2 MODULATORS GLAXO GROUP LIMITED (GB) 2004-03-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180200408-A1 NEW HYDROGELS HAVING A SILYLATED STRUCTURE, AND METHOD FOR OBTAINING SAME ILK, CD44, VCL CYP3A4 3044/4885MEN1 3902/4885MAPT 1436/4885
US-20210393855-A1 NEW HYDROGELS HAVING A SILYLATED STRUCTURE, AND METHOD FOR OBTAINING SAME ILK, CD44, VCL CYP3A4 2930/4885MEN1 3985/4885MAPT 1452/4885
US-11299590-B2 Process for preparation of bioorganic nylon polymers and their use as antibacterial material DDC, PDCD2L, PCBP1 CYP3A4 3177/4885MEN1 1876/4885MAPT 3384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.